FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1546117988> ?p ?o ?g. }

• W1546117988 endingPage "3562" @default.
• W1546117988 startingPage "3553" @default.
• W1546117988 abstract "// Marco Fiorillo 1,2,3 , Andrea F. Verre 4 , Maria Iliut 4 , Maria Peiris-Pag é s 1,2 , Bela Ozsvari 1,2 , Ricardo Gandara 1,2 , Anna Rita Cappello 3 , Federica Sotgia 1,2 , Aravind Vijayaraghavan 4 and Michael P. Lisanti 1,2 1 The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, UK 2 The Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK 3 The Department of Pharmacy, Health and Nutritional Sciences, The University of Calabria, Italy 4 School of Materials and National Graphene Institute, University of Manchester, UK Correspondence: Michael P. Lisanti, email: // Aravind Vijayaraghavan, email: // Keywords : nanomaterials, graphene oxide, cancer stem cells, multiple cancer types: breast, ovarian Received : January 01, 2015 Accepted : February 12, 2015 Published : February 24, 2015 Abstract Tumor-initiating cells (TICs), a.k.a. cancer stem cells (CSCs), are difficult to eradicate with conventional approaches to cancer treatment, such as chemo-therapy and radiation. As a consequence, the survival of residual CSCs is thought to drive the onset of tumor recurrence, distant metastasis, and drug-resistance, which is a significant clinical problem for the effective treatment of cancer. Thus, novel approaches to cancer therapy are needed urgently, to address this clinical need. Towards this end, here we have investigated the therapeutic potential of graphene oxide to target cancer stem cells. Graphene and its derivatives are well-known, relatively inert and potentially non-toxic nano-materials that form stable dispersions in a variety of solvents. Here, we show that graphene oxide (of both big and small flake sizes) can be used to selectively inhibit the proliferative expansion of cancer stem cells, across multiple tumor types. For this purpose, we employed the tumor-sphere assay, which functionally measures the clonal expansion of single cancer stem cells under anchorage-independent conditions. More specifically, we show that graphene oxide effectively inhibits tumor-sphere formation in multiple cell lines, across 6 different cancer types, including breast, ovarian, prostate, lung and pancreatic cancers, as well as glioblastoma (brain). In striking contrast, graphene oxide is non-toxic for “bulk” cancer cells (non-stem) and normal fibroblasts. Mechanistically, we present evidence that GO exerts its striking effects on CSCs by inhibiting several key signal transduction pathways (WNT, Notch and STAT-signaling) and thereby inducing CSC differentiation. Thus, graphene oxide may be an effective non-toxic therapeutic strategy for the eradication of cancer stem cells, via differentiation-based nano-therapy." @default.
• W1546117988 created "2016-06-24" @default.
• W1546117988 creator A5014005480 @default.
• W1546117988 creator A5016681558 @default.
• W1546117988 creator A5021882845 @default.
• W1546117988 creator A5047846477 @default.
• W1546117988 creator A5055376572 @default.
• W1546117988 creator A5068484663 @default.
• W1546117988 creator A5075230540 @default.
• W1546117988 creator A5077906608 @default.
• W1546117988 creator A5085935743 @default.
• W1546117988 creator A5091000979 @default.
• W1546117988 date "2015-02-24" @default.
• W1546117988 modified "2023-10-17" @default.
• W1546117988 title "Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”" @default.
• W1546117988 cites W1707356941 @default.
• W1546117988 cites W1980419364 @default.
• W1546117988 cites W1980714336 @default.
• W1546117988 cites W1980806488 @default.
• W1546117988 cites W1995384957 @default.
• W1546117988 cites W1997227711 @default.
• W1546117988 cites W2001106724 @default.
• W1546117988 cites W2002579647 @default.
• W1546117988 cites W2013328140 @default.
• W1546117988 cites W2015706810 @default.
• W1546117988 cites W2023529679 @default.
• W1546117988 cites W2024711136 @default.
• W1546117988 cites W2028544780 @default.
• W1546117988 cites W2034388492 @default.
• W1546117988 cites W2037843283 @default.
• W1546117988 cites W2045477445 @default.
• W1546117988 cites W2052092440 @default.
• W1546117988 cites W2056278562 @default.
• W1546117988 cites W2064442490 @default.
• W1546117988 cites W2071946741 @default.
• W1546117988 cites W2075663237 @default.
• W1546117988 cites W2086828029 @default.
• W1546117988 cites W2094187675 @default.
• W1546117988 cites W2101885447 @default.
• W1546117988 cites W2102085111 @default.
• W1546117988 cites W2103300371 @default.
• W1546117988 cites W2126647999 @default.
• W1546117988 cites W2135479172 @default.
• W1546117988 cites W2140313746 @default.
• W1546117988 cites W2140746165 @default.
• W1546117988 cites W2146573095 @default.
• W1546117988 cites W2170258102 @default.
• W1546117988 cites W2343291871 @default.
• W1546117988 cites W38755132 @default.
• W1546117988 cites W4233194460 @default.
• W1546117988 cites W4237923469 @default.
• W1546117988 doi "https://doi.org/10.18632/oncotarget.3348" @default.
• W1546117988 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4414136" @default.
• W1546117988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25708684" @default.
• W1546117988 hasPublicationYear "2015" @default.
• W1546117988 type Work @default.
• W1546117988 sameAs 1546117988 @default.
• W1546117988 citedByCount "170" @default.
• W1546117988 countsByYear W15461179882015 @default.
• W1546117988 countsByYear W15461179882016 @default.
• W1546117988 countsByYear W15461179882017 @default.
• W1546117988 countsByYear W15461179882018 @default.
• W1546117988 countsByYear W15461179882019 @default.
• W1546117988 countsByYear W15461179882020 @default.
• W1546117988 countsByYear W15461179882021 @default.
• W1546117988 countsByYear W15461179882022 @default.
• W1546117988 countsByYear W15461179882023 @default.
• W1546117988 crossrefType "journal-article" @default.
• W1546117988 hasAuthorship W1546117988A5014005480 @default.
• W1546117988 hasAuthorship W1546117988A5016681558 @default.
• W1546117988 hasAuthorship W1546117988A5021882845 @default.
• W1546117988 hasAuthorship W1546117988A5047846477 @default.
• W1546117988 hasAuthorship W1546117988A5055376572 @default.
• W1546117988 hasAuthorship W1546117988A5068484663 @default.
• W1546117988 hasAuthorship W1546117988A5075230540 @default.
• W1546117988 hasAuthorship W1546117988A5077906608 @default.
• W1546117988 hasAuthorship W1546117988A5085935743 @default.
• W1546117988 hasAuthorship W1546117988A5091000979 @default.
• W1546117988 hasBestOaLocation W15461179881 @default.
• W1546117988 hasConcept C121608353 @default.
• W1546117988 hasConcept C126322002 @default.
• W1546117988 hasConcept C143998085 @default.
• W1546117988 hasConcept C2779013556 @default.
• W1546117988 hasConcept C2780110267 @default.
• W1546117988 hasConcept C502942594 @default.
• W1546117988 hasConcept C530470458 @default.
• W1546117988 hasConcept C55427017 @default.
• W1546117988 hasConcept C71924100 @default.
• W1546117988 hasConcept C96232424 @default.
• W1546117988 hasConceptScore W1546117988C121608353 @default.
• W1546117988 hasConceptScore W1546117988C126322002 @default.
• W1546117988 hasConceptScore W1546117988C143998085 @default.
• W1546117988 hasConceptScore W1546117988C2779013556 @default.
• W1546117988 hasConceptScore W1546117988C2780110267 @default.
• W1546117988 hasConceptScore W1546117988C502942594 @default.
• W1546117988 hasConceptScore W1546117988C530470458 @default.
• W1546117988 hasConceptScore W1546117988C55427017 @default.
• W1546117988 hasConceptScore W1546117988C71924100 @default.

• next